ATLANTA--(BUSINESS WIRE)--MIV Therapeutics, Inc. (OTCBB: MIVI) (Frankfurt: MIVN), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announced today the effectiveness of the reverse split of its common stock in the ratio of 1-for-10. The Company’s common stock will begin trading at the market opening on June 30, 2008 on a split-adjusted basis under the symbol MIVI. The reverse split is intended to enable the Company to increase its marketability to institutional investors.
